KRAS and non-small cell lung carcinoma: The phase II KRYSTAL-1 study evaluated the use of adagrasib in a cohort of 64 previously treated patients with advanced solid tumors harboring KRAS G12C mutations (excluding colorectal and NSCLC), including 21 with advanced PDAC, of whom 76.2% had received two or more lines of prior chemotherapy—Table 1 [99].